LUNG TUMOR PROJECT

肺癌是美国癌症死亡的主要原因，大多数肺癌患者的预后仍然很差。最好的预后是I期NSCLC患者，但只有50%的患者存活超过5年。为什么一些早期I期肺癌患者表现非常差，而另一些患者表现良好，这可能是由于分配给该分类的肺肿瘤的异质性。目前先进的技术可以对个体肿瘤的大量基因进行分子评估，有可能为这一重要问题提供新的见解。拟议的研究的主要重点，是检查mRNA表达谱使用cDNA阵列，和蛋白质表达谱使用定量的二维凝胶电泳（2D凝胶）在非小细胞肺癌设计一种新的方法，这些肿瘤的子集进行分类。数据分析将包括与临床和其他分子遗传学数据的相关性，以及与本项目研究的其他常见上皮肿瘤的分子谱的相关性。已经建立了一个由具有肺癌专门知识的调查人员组成的网络，为该项目提供必要的资源。具体目标I是确定目前属于I期肺腺癌的肿瘤的基于分子的分类，该分类更能预测该组肿瘤的临床行为。特定目的II是确定目前属于I期鳞状细胞肺癌的肿瘤的基于分子的分类，其更能预测该组肿瘤的临床行为。 在5年期间，将检查总共200例I期肺腺癌和鳞状细胞癌。将分析数据，以了解肿瘤组之间的基因和蛋白质表达模式，以及已知突变、临床结果、吸烟状况以及与其他常见的结肠和卵巢上皮肿瘤的比较。

Lung cancer is the major cause of cancer death in the United States and the prognosis for most patients with lung cancer has remained poor. The best prognosis is for patients with Stage I NSCLC, but only 50% survive beyond 5 years. Why some patients who present with early stage I lung cancers do very poorly while others do well may be due the heterogeneity of lung tumors assigned to this classification. Advanced in current technologies, which allow the molecular assessment of a large number of genes from individual tumors, have the potential to provide new insight into this important question. The major focus of the proposed studies, is to examined both the mRNA expression profile using cDNA arrays, and the protein expression profiles using quantitative two-dimensional gel electrophoresis (2D gels) in non-small cell lung cancers to devise a novel means of classifying subsets of these tumors. Data analyses will include correlations with clinical and other molecular genetic data and with molecular profiles of other common epithelial tumors to be studied in this project. A network has been set up consisting of investigators with lung cancer expertise to provide the necessary resources for this project. Specific Aim I is to determine a molecular-based classification of tumors that currently belong to stage I lung adenocarcinomas that is more predictive of clinical behavior for this group of tumors. Specific Aim II is to determine a molecular based classification of tumors that currently belong to stage I squamous cell lung carcinomas that is more predictive of clinical behavior of this group of tumors. A total of 200 stage I lung adenocarcinomas and squamous cell carcinomas will be examined during the 5 year period. Data will be analyzed for patterns of gene and protein expression among groups of tumors and with respect to known mutations, clinical outcome, smoking status and comparisons to other common epithelial tumors of the colon and ovary.